[Prescription of new HCV-drugs - what has to be considered judicially].
A unique specialty of the German public health insurance system is the option to hold a physician liable for the cost of medication considered not to be in line with the indication or to not to be used in a cost efficient way. Due to the high prices of direct acting antivirals (DAA) against the hepatitis C virus the potential financial losses are substantial. In addition, some of the public health insurance companies have already announced their intent to challenge the use of DAA. In this context the options as to how to minimise this risk are analysed within the given legal environment.